Abstract
Background: Patient-reported outcomes (PROs) are health outcome measures reported directly from patients that experienced a specific medical treatment. These PROs are used to help researchers and clinicians appraise the efficacy of said treatment. We investigated medical treatments specific to peripheral nerve blocks (PNBs) by questioning the completeness of reporting of randomized controlled trials (RCTs) with PROs related to PNBs as well as the association between reporting completeness and trial characteristics.
Methods: We used MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) to search for RCT publications investigating PNBs. RCTs were screened, and those that met inclusion criteria were extracted using the Consolidated Standards of Reporting Trials - Patient-Reported Outcome (CONSORT-PRO) extension adaptation and the Cochrane Collaboration Risk of Bias (RoB 2.0) tool. Adherence to the CONSORT-PRO guidelines was calculated as well as a linear bivariate regressions analysis to assess the relationship between reporting completeness and trial characteristics.
Results: Sixty five RCTs met inclusion criteria and were extracted and analyzed. We found an overall completion percentage of 46.80% (SD=17.36). There was a significant difference (p=0.035) that was found in completeness of reporting between RCTs with PROs established as a primary outcome (49.27%, SD=16.58) versus a secondary outcome (38.57%, SD=17.92). Another significant finding was that the length of PRO follow-up between 6+ months to 1 year was 16.24% more complete when compared to 3 months or less (p=0.006). No other significant differences were found within our analysis.
Conclusion: We found that incomplete reporting was common among PROs within our included RCTs investigating PNBs. PROs allow clinicians to better understand patients’ experiences regarding the interventions that they receive. Applying these patient reported measures into clinical practices allows enhanced overall healthcare. Thus, increased adherence to the CONSORT-PRO statement is encouraged to improve PRO reporting.
Methods: We used MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) to search for RCT publications investigating PNBs. RCTs were screened, and those that met inclusion criteria were extracted using the Consolidated Standards of Reporting Trials - Patient-Reported Outcome (CONSORT-PRO) extension adaptation and the Cochrane Collaboration Risk of Bias (RoB 2.0) tool. Adherence to the CONSORT-PRO guidelines was calculated as well as a linear bivariate regressions analysis to assess the relationship between reporting completeness and trial characteristics.
Results: Sixty five RCTs met inclusion criteria and were extracted and analyzed. We found an overall completion percentage of 46.80% (SD=17.36). There was a significant difference (p=0.035) that was found in completeness of reporting between RCTs with PROs established as a primary outcome (49.27%, SD=16.58) versus a secondary outcome (38.57%, SD=17.92). Another significant finding was that the length of PRO follow-up between 6+ months to 1 year was 16.24% more complete when compared to 3 months or less (p=0.006). No other significant differences were found within our analysis.
Conclusion: We found that incomplete reporting was common among PROs within our included RCTs investigating PNBs. PROs allow clinicians to better understand patients’ experiences regarding the interventions that they receive. Applying these patient reported measures into clinical practices allows enhanced overall healthcare. Thus, increased adherence to the CONSORT-PRO statement is encouraged to improve PRO reporting.
| Original language | American English |
|---|---|
| Pages | 78 |
| State | Published - 18 Feb 2022 |
| Event | Oklahoma State University Center for Health Sciences Research Week 2022 : Poster Presentation - Oklahoma State University Center for Health Sciences, Tulsa, United States Duration: 14 Feb 2022 → 18 Feb 2022 |
Conference
| Conference | Oklahoma State University Center for Health Sciences Research Week 2022 |
|---|---|
| Country/Territory | United States |
| City | Tulsa |
| Period | 14/02/22 → 18/02/22 |